Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). DMK Pharmaceuticals's share price for the quarter that ended in Sep. 2023 was $0.689. DMK Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 10.09 Mil. Therefore, DMK Pharmaceuticals's market cap for the quarter that ended in Sep. 2023 was $6.96 Mil.
DMK Pharmaceuticals's quarterly market cap
declined
from Mar. 2023 ($19.30 Mil) to Jun. 2023 ($6.72 Mil) but then
increased
from Jun. 2023 ($6.72 Mil) to Sep. 2023 ($6.96 Mil).
DMK Pharmaceuticals's annual market cap
increased
from Dec. 2020 ($45.52 Mil) to Dec. 2021 ($90.50 Mil) but then
declined
from Dec. 2021 ($90.50 Mil) to Dec. 2022 ($25.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. DMK Pharmaceuticals's Enterprise Value for Today is $-0.18 Mil.
DMK Pharmaceuticals Market Cap Historical Data
The historical data trend for DMK Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DMK Pharmaceuticals's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Market Cap falls into.
DMK Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
DMK Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals (OTCPK:DMKPQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
DMK Pharmaceuticals Market Cap Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 